Market Pathways Scorecard: EUDAMED Snapshot
An infographic look at what has been entered in the EU's EUDAMED database so far as the May 28 date for mandatory registration of certificates, devices, companies, and more approaches.
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
An infographic look at what has been entered in the EU's EUDAMED database so far as the May 28 date for mandatory registration of certificates, devices, companies, and more approaches.
Years of macro and policy headwinds have dragged down medtech valuations, but the industry may be entering a period where fundamentals and innovation reignite investor sentiment. Strategics and private equity alike are repositioning their portfolios around new, higher‑growth opportunities. The AAOS meeting in New Orleans will offer a look at how aggressively the sector is preparing for its next growth leg. Watch our interview with Ryan Zimmerman of BTIG and Masha Dumanis of Kx Advisors.
A MHRA proposal would allow firms to rely on EU MDR/IVDR CE marks indefinitely in Great Britain. Excerpted from Pathways’ Picks February 18: Britain Gives in to the CE Mark, CMS ACCESS Updates, South Korea Wellness Policy.